Janux Therapeutics JANX Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's free cash flow yield?
- Janux Therapeutics (JANX) reported free cash flow yield of -9.3% in Q1 2026.
- How has Janux Therapeutics's free cash flow yield changed year-over-year?
- Janux Therapeutics's free cash flow yield decreased by 218.3% year-over-year, from -2.9% to -9.3%.
- What is the long-term trend for Janux Therapeutics's free cash flow yield?
- Over 4 years (2021 to 2025), Janux Therapeutics's free cash flow yield has grown at a 45.1% compound annual growth rate (CAGR), from -2.3% to -10%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.